Q4 Earnings Forecast for BioNTech Issued By HC Wainwright

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) - Equities researchers at HC Wainwright cut their Q4 2025 earnings estimates for shares of BioNTech in a research note issued to investors on Monday, June 16th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of $0.51 for the quarter, down from their prior estimate of $0.52. HC Wainwright currently has a "Buy" rating and a $138.00 target price on the stock. The consensus estimate for BioNTech's current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech's Q1 2026 earnings at ($2.23) EPS, Q2 2026 earnings at ($2.25) EPS, Q3 2026 earnings at ($0.72) EPS and FY2026 earnings at ($5.35) EPS.

Several other research firms have also recently commented on BNTX. Canaccord Genuity Group restated a "buy" rating and set a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. The Goldman Sachs Group began coverage on BioNTech in a research note on Thursday, May 29th. They set a "neutral" rating and a $110.00 price objective on the stock. Leerink Partners set a $112.00 price target on BioNTech in a research note on Monday, June 2nd. JPMorgan Chase & Co. decreased their price target on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Finally, BMO Capital Markets lifted their price objective on BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $137.86.

BioNTech Stock Down 1.3%

Shares of BNTX opened at $104.97 on Wednesday. The firm has a market cap of $25.23 billion, a P/E ratio of -30.87 and a beta of 1.29. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01. The company's 50-day moving average price is $101.59 and its 200 day moving average price is $107.87. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49.

Institutional Trading of BioNTech

Hedge funds have recently made changes to their positions in the stock. Banque Cantonale Vaudoise purchased a new stake in shares of BioNTech during the first quarter valued at approximately $36,000. Jones Financial Companies Lllp raised its position in shares of BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after purchasing an additional 246 shares during the period. Banque Transatlantique SA purchased a new stake in BioNTech in the 1st quarter worth $80,000. Quintet Private Bank Europe S.A. lifted its stake in BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after purchasing an additional 700 shares in the last quarter. Finally, Allianz SE bought a new stake in shares of BioNTech in the 4th quarter worth about $90,000. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.